Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
[Discussion on the Focus of On-site Inspection of Clinical Trials of Lung Cancer Targeted Therapy and Immunotherapy Drugs].
0
Zitationen
4
Autoren
2022
Jahr
Abstract
As lung cancer targeted therapy and immunotherapy drugs are the current hot spot in the research and development area of new anti-tumor drugs, the amount of clinical trial in this area is increasing year by year. On the basis of combing the on-site inspections of drug registration clinical trials from 2019 to 2021, combined with the characteristics of lung cancer targeted therapy and immunotherapy drugs, this paper discusses the focus of on-site inspection of clinical trials of such drugs, and puts forward suggestions for the compliant implementation of lung cancer clinical trials. .
Ähnliche Arbeiten
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 · 28.943 Zit.
TNM Classification of Malignant Tumours
1987 · 16.123 Zit.
A survey on deep learning in medical image analysis
2017 · 13.625 Zit.
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
2011 · 10.776 Zit.
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
2010 · 9.111 Zit.